Date:4/9/2008

ease contains forward-looking statements including, but not limited to, those that infer that Cardiac Science Corporation's future revenue and profits may grow as a result of sales of defibrillation products. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks that are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2007. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Company Contact: Investor Contact: Media Contact:

Mike Matysik Jenifer Kirtland Christopher Gale

Cardiac Science Corporation EVC Group, Inc. EVC Group, Inc.

Sr. Vice President and CFO (415) 896-6820 (201) 646-5431

(425) 402-2009 (203) 570-4681

cgale@evcgroup.com

CSCX-G

'/>"/>

SOURCE Cardiac Science Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
5. Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand
6. Pharmaxis to Apply to Market Bronchitol in Australia
7. RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
11. Notal Vision chooses TrialStats ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial